Antimalarials is re-evaluation needed?

Journal of Clinical Rheumatology

Volumn 4, Issue 2, 1998, Pages 50-51

  Rynes, Richard I ^a  

^a Arthritis Associates of Puget Sound   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008502375     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/00124743-199804000-00002     Document Type: Article

References (18)

1. Davis MJ, Dawes PT, Fowler PD, Clark S, Fisher J, Shadforth MP. Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991;30:451.
2. Clark P, Cassas F, Tugwell P, Medina C, Gheno C, Tenorio G, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis; a randomized controlled study. Ann Intern Med 1993; 119.1067.
3. The HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis. The HERA Study. Ann J Med 1996; 98:156.
4. The Canadian Hydroxychloroquine Study Group. A randomized study of the effects of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991 324:150.
5. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanuo R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984;10:592.
6. Olson NY, Lindlsey CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheum 1989;16:12.
7. Kammer GM, Soter NA, Gibson DJ, Schut PH. Psoriatic arthritis: A clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979;9:75.
8. Youssef W, Yan A, Russell A. Palindromic rheumatism: A response to chloroquine. J Rheum 1991;18:35.
9. Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Brenndan Moore S. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1998;17:221.
10. Manners PJ, Ansell DM. Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 1986;77:99.
11. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howel FV. Treatment of primary Sjogren’s syndrome with hydroxychloroquine. Am J Med 1988;85:62.
12. Wallace J, Metzger AL, Setter VDU, Trundle BA, Ken PA. Cholesterol lowering effect of hydroxychloroquine (Plaquenil) in rheumatoid disease patients. Reversal of deleterious effects of steroids on lipids. Am J Med 1990;89: 322.
13. Hoods HEN, Quismorio FP jr, Wickham E, Blankenhom DH. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine: in patients with SLE. J Rheum 1993;20:661.
14. Albert DA, Debois LKL, Lu KF. Antimalarial mocular toxicity - A critical appraisal. J Clin Rheum. Forthcoming 1998.
15. MacKenzie HA. Dose refinements in longterm therapy of rheumatoid arthritis with antimaiarials. Am J Med 1983;75 Suppl:40.
16. Toxin DR, Choral GB, Rynes RI. Hydroxychloroquine. A seven-year experience. Arch Ophthalmol 1982;100:81-3.
17. Rynes RI. Antimalarial drugs in the treatment of rheumatologic diseases. Brit J Rheumatol 1997:36:799.
18. Easterbrook M. Dose relationships in patients with early chloroquine retinopathy. J Rheum 1987; 14:472.